METHOD OF RADIONUCLIDAL DIAGNOSTICS OF LARYNGEAL AND PHARYNGOPHARYNGEAL CANCER Russian patent published in 2019 - IPC A61B6/03 A61K103/10 A61P43/00 A61M36/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology and radiation diagnostics, and can be used for radionuclide diagnostics of laryngeal and pharyngopharyngeal cancer. Radiopharmaceutical is made just before its intravenous administration. To do this, 4 ml of sodium pertechnetate Na_99mTcO₄ is injected under aseptic conditions with a syringe from the generator to the reagent vial. Composition of the reagent is as follows: 1-thio-D-glucose sodium salt hydrate - 0.625 mg, tin 2-water dichloride - 0.044–0.052 mg, ascorbic acid - not more than 0.125 mg, sodium chloride 8.0–10.0 mg, water for injection - up to 1 ml. Contents of the vial is mixed by shaking and incubated at room temperature for 30 minutes until complete dissolution of the reagent. Resulting radiopharmaceutical is injected on the basis of technetium-99m labelled derivative of glucose at a dose of 500 MBq. 40 minutes after radiopharmaceutical injection, single-photon emission computed tomography is performed on a two-detector gamma camera. Resulting images are post-processed. Malignant neoplasm is diagnosed when visualizing the sites of hyperfixation of the radiopharmaceutical in the projection of the larynx or hypopharynx.

EFFECT: method provides improved accuracy and informativeness of radionuclide diagnostics of laryngeal and hypopharyngeal cancer due to the use of radiopharmaceuticals based on technetium-99m-labelled derivative of glucose and single-photon emission computed tomography.

1 cl, 2 dwg, 1 tbl, 1 ex